Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Abstract Background Targeted lung denervation (TLD) is a novel bronchoscopic therapy that disrupts parasympathetic pulmonary nerve input to the lung reducing clinical consequences of cholinergic hyperactivity. The AIRFLOW-1 study assessed safety and TLD dose in patients with moderate-to-severe, symp...

Full description

Bibliographic Details
Main Authors: Pison Christophe, L. Shah Pallav, Slebos Dirk-Jan, Ninane Vincent, Janssens Wim, Perez Thierry, Kessler Romain, Deslee Gaetan, L. Garner Justin, E. Hartman Jorine, Degano Bruno, Mayr Anna, Mayse Martin, D. Peterson Alexander, Valipour Arschang
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Respiratory Research
Subjects:
COPD
Nerves
Targeted lung denervation
Acetylcholine
Anticholinergic
Bronchoscopy
Online Access:https://doi.org/10.1186/s12931-021-01664-5

Internet

https://doi.org/10.1186/s12931-021-01664-5

Similar Items